Popular in Professional

Business

The Allegory of the Favela: The Multifaceted Effects of Socioeconomic Mobility

University of Pennsylvania Leandro S. Pongeluppe

Architecture

Connecting Cities and Nature

University of Virginia Timothy Beatley

Human Rights Law

Human Rights and Corruption: Problems and Potential of Individualising a Systemic Problem

Max Planck Institute Anne Peters

Finance

Chinese Exchange Rate Policy: Lessons for Global Investors

University of California San Diego Michael Melvin

Law

A statistical approach to law school citation rankings

University of Virginia Joshua Fischman

Education

Firm Performance Pay as Insurance against Promotion Risk

Stockholm School of Economics Alvin Chen

Cytotoxic Activity and Anti-Migratory Effect of Berberine-Phytantriol Liquid Crystalline on Non-Small-Cell Lung Cancer

View more insights in Professional - Pharmacy

View more figures from University of Technology Sydney

View the page of Kamal Dua

Read the Study

Next in Pharmacy

The many faces of the AMPA-type ionotropic glutamate receptor

Derek Bowie | McGill University

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs

Janice Aldrich-Wright | Western Sydney University

Kamal Dua aimed to formulate an optimized formulation of berberine-phytantriol-loaded liquid crystalline nanoparticles (BP-LCNs) and to investigate the in vitro anti-cancer activity in a human lung adenocarcinoma A549 cell line.

Image courtesy of interviewee. June 5, 2024

Log-in or Sign-up to Faculti
Currently viewing this subject insight as a guest. You have insight(s) remaining for this month. Login to view 8000+ figures on the platform.

Generating Workspace...

Export as PDF

This video is a detailed presentation regarding research conducted by a team at the Graduate School of Health and Discipline of Pharmacy at the University of Technology Sydney. The research primarily focuses on lung diseases, particularly lung cancer, asthma, and COPD (chronic obstructive pulmonary disease).

In the study, the team investigates phytol-loaded liquid crystalline nanoparticles containing berberine, a natural compound known for its various therapeutic effects, including use in treating diabetes and high cholesterol. They emphasize berberine’s efficacy against non-small cell lung cancer, a prevalent type of lung cancer accounting for about 85% of cases.

The research highlights the issue of berberine's low water solubility, which hinders its absorption and efficacy. The study’s novel approach uses nanoparticles to improve the solubility and delivery of berberine, enhancing its therapeutic potential while reducing side effects and required dosages.

The study demonstrates that the berberine-loaded nanoparticles effectively inhibit cancer cell proliferation, migration, and colony formation in vitro. Key proteins and genes associated with lung cancer pathogenesis were positively impacted by the treatment.

The research is collaborative, integrating various scientific fields and includes a wider vision for animal and potentially human trials in the future. The team is also working on developing dry powder inhalers for delivering these nanoparticles directly to the lungs.

In summary, this study showcases the promising potential of berberine-loaded nanoparticles as a therapeutic option for treating lung cancer, while also addressing challenges related to drug delivery and bioavailability.

Language:

Export as PDF

X-TIMESTAMP-MAP:LOCAL=00:00:00.000,MPEGTS=900000

00:00.425 --> 00:02.385
I in terms of my laboratory,

00:02.565 --> 00:04.385
I'm based at the Graduate School of Health

00:04.405 --> 00:06.825
and Discipline of Pharmacy at University

00:06.825 --> 00:10.345
of Technology Sydney, where my research team primarily focus

00:10.445 --> 00:11.945
on various lung diseases

00:12.215 --> 00:16.545
with the main emphasis on lung cancer, asthma, and COPD.

00:16.845 --> 00:19.545
Now, in today's study, we are going to talk more about

00:19.605 --> 00:23.105
and discuss about the phytol, loaded,

00:23.165 --> 00:25.945
liquid crystalline nanoparticles containing berberine.

00:26.245 --> 00:27.585
So we have understand,

00:27.645 --> 00:29.545
and we have studied the efficacy

00:29.605 --> 00:31.865
of these nanoparticles in lung cancer.

00:32.995 --> 00:35.045
Lung cancer is actually highly prevalent cancer,

00:35.665 --> 00:39.005
and with over more than 2 million new cases in the

00:39.005 --> 00:41.045
worldwide, it reported in just 2020

00:41.225 --> 00:42.925
and it's been rising every year.

00:43.705 --> 00:47.005
Now, this lung cancer is one of the major cause

00:47.005 --> 00:48.005
of the deaths globally,

00:48.305 --> 00:50.405
and if we look at the statistics, there are

00:50.405 --> 00:54.685
around 1.79 million reported deaths, which contributes

00:54.685 --> 00:57.845
to almost 18% of the total cancer deaths

00:57.845 --> 00:59.325
around the globe in 2020.

01:00.595 --> 01:02.215
Now, there are two types of the lung cancer.

01:02.355 --> 01:04.815
One is called as a small cell lung cancer, other is called

01:04.815 --> 01:06.295
as a non-small cell lung cancer.

01:06.915 --> 01:08.495
Our studies emphasized

01:08.515 --> 01:10.775
and focused on the non-small cell lung cancer.

01:11.405 --> 01:14.215
This why we have studied on non-small cell lung cancer

01:14.215 --> 01:18.935
because this is a cancer which actually makes up to 85%

01:19.035 --> 01:20.375
of the lung cancer cases,

01:21.035 --> 01:24.135
and it is, it still remains a major most common

01:24.135 --> 01:25.215
cause of the lung cancer.

01:25.425 --> 01:29.375
Among the both, the only difference between both of these is

01:29.565 --> 01:32.615
that the small cell lung cancer is still an aggressive one,

01:32.875 --> 01:34.655
but the nonsmall cell lung cancer,

01:34.655 --> 01:36.175
because of its high prevalence,

01:36.195 --> 01:37.575
we have undertook this study.

01:39.155 --> 01:40.775
The, the small cell lung cancer.

01:40.955 --> 01:43.895
In, in, in that cancer, it's a metastasis is more

01:43.955 --> 01:45.815
as compared to the non-small cell cancer,

01:45.825 --> 01:47.735
which mostly happened in the lymph nodes.

01:48.635 --> 01:52.895
In our study we have, we undertook a study on a natural

01:53.415 --> 01:56.255
compound because around the globe people are getting very

01:56.255 --> 01:59.015
much aware nowadays about the alternative

01:59.015 --> 02:00.215
and complementary medicine.

02:01.095 --> 02:02.935
Everyone think and takes one

02:02.935 --> 02:07.215
or the other form of the natural compound in their diet or

02:07.435 --> 02:09.255
or to treat any of their elements.

02:09.715 --> 02:13.175
The best example, which I usually give in every talk is when

02:13.175 --> 02:15.095
someone really want to even lose a weight,

02:15.165 --> 02:16.775
they go on their diet with salad.

02:17.275 --> 02:19.495
And that salad actually is itself is nothing,

02:19.515 --> 02:22.775
but it's a kind of, plant-based products,

02:22.825 --> 02:24.175
which you are eating and

02:24.175 --> 02:26.775
to cut your certain metabolism into the body.

02:27.435 --> 02:31.095
In a same way, the pharmaceuticals are having an abundant

02:31.325 --> 02:32.695
therapeutic potential.

02:33.515 --> 02:36.215
In this study, we have used berberine.

02:37.015 --> 02:39.735
Berberine actually, in scientific terms is an

02:39.965 --> 02:41.495
isoc and alkaloid.

02:42.835 --> 02:46.055
It is actually also been available in the market in terms

02:46.055 --> 02:49.535
of the chemical compounds called as berberine hydrochloride.

02:50.865 --> 02:53.875
It's already been used in ancient history

02:54.295 --> 02:56.115
and for long ago by Chinese

02:56.455 --> 02:58.395
and also in the Ayurvedic medicine

02:58.735 --> 03:03.525
to treat various elements like diabetes, high cholesterol,

03:03.915 --> 03:06.605
high blood pressure, and various other conditions.

03:07.265 --> 03:09.965
But it was not explored on lung cancer.

03:10.545 --> 03:12.765
And this is how our study came into the picture,

03:12.905 --> 03:15.005
and we were the first one who demonstrated

03:15.005 --> 03:17.725
that it is quite effective in the small

03:17.795 --> 03:19.125
non-small cell lung cancer.

03:19.705 --> 03:22.565
Now, this article has been really got a very

03:22.565 --> 03:23.605
high alt metric.

03:23.905 --> 03:26.525
It has already been posted by, across the globe

03:26.545 --> 03:28.005
by multiple news channels.

03:28.875 --> 03:33.335
And so what we have seen here is that all these berberine,

03:33.335 --> 03:34.455
which is been used,

03:34.805 --> 03:36.895
they can treat several metabolic health

03:36.895 --> 03:38.055
condition, as I mentioned.

03:38.395 --> 03:40.735
But there is a problem with this perine.

03:42.265 --> 03:45.845
The burberine itself is a very water insoluble and

03:45.845 --> 03:48.245
because of its poorly water-soluble nature,

03:48.505 --> 03:50.525
its absorption in the body is very low,

03:51.355 --> 03:54.175
and that can even cause toxicity if being given

03:54.195 --> 03:55.295
at a higher doses.

03:56.245 --> 03:57.985
So because its absorption is low,

03:58.005 --> 03:59.945
and in scientific term, we usually call it

03:59.945 --> 04:01.665
as an bioavailability.

04:01.805 --> 04:04.705
So the bioavailability of this drug is very, very low

04:04.705 --> 04:06.505
because it's poorly water-soluble.

04:07.185 --> 04:10.005
So what we have used in our studies, we have used a very

04:10.525 --> 04:13.125
advanced novel concept of nanoparticles.

04:13.955 --> 04:16.885
Nanoparticles are nothing, but they are very tiny balls.

04:16.945 --> 04:19.405
The best example I can give is like a tennis ball,

04:19.825 --> 04:21.325
and it is hollow from inside

04:21.705 --> 04:24.325
and you fill your drug in the middle, in the hollow part

04:24.325 --> 04:26.835
of the tennis ball, the outer part

04:26.835 --> 04:28.595
of the tennis ball is a polymer sheath.

04:28.935 --> 04:32.835
In our case, we have used python roll is a polymer.

04:33.055 --> 04:34.795
So when it's been gone in and and

04:34.895 --> 04:36.835
and been taken up by the organ

04:37.015 --> 04:41.075
or the tissue, which is lung hair, it retains on the surface

04:41.415 --> 04:43.635
and it slowly dissolved the polymer

04:43.855 --> 04:46.235
and the drug release for a longer duration of time.

04:46.775 --> 04:49.435
So it means the patient don't have to take multiple dose,

04:50.055 --> 04:51.835
the patient have a better compliance,

04:52.255 --> 04:54.355
and it also reduces the side effect.

04:55.215 --> 04:57.995
The best example and the best application

04:58.095 --> 04:59.915
and useful nature

05:00.095 --> 05:04.035
of these nanoparticle is it helps even also improving the

05:04.035 --> 05:05.275
solubility of berberine.

05:05.895 --> 05:08.435
So when berberine is already poorly water soluble

05:08.435 --> 05:10.635
and we prepare in form of a nanoparticles,

05:11.015 --> 05:13.875
it releases the drug for a longer duration of time.

05:14.415 --> 05:15.755
That's the whole idea

05:15.895 --> 05:18.755
and the concept we have used in our study.

05:19.015 --> 05:20.515
That's a very good question actually.

05:20.585 --> 05:23.755
It's, this is a question which is, this is

05:23.755 --> 05:25.195
what we have actually probed

05:25.195 --> 05:29.315
and elucidated in our study how exactly it had worked out.

05:29.695 --> 05:32.355
So what we have done, as I mentioned, that

05:32.775 --> 05:35.475
it has been incorporated into a liquid crystalline

05:35.505 --> 05:37.995
nanoparticles and those nanoparticles,

05:38.295 --> 05:41.795
we are still been trying to get it into a dry powder inhaler

05:41.895 --> 05:45.115
so that when patient can have a puff, it can go directly on

05:45.215 --> 05:48.675
and deposit on the epithelial cells and release the drug.

05:49.775 --> 05:52.875
Now, before, actually I can tell you more in terms of the,

05:53.295 --> 05:56.355
how the mechanism has happened.

05:56.615 --> 05:58.045
It is really important to know

05:58.045 --> 06:00.405
what is the methodology we have used in the study.

06:01.445 --> 06:03.865
Now, in this study we have,

06:04.005 --> 06:06.225
we have done all the in vitro studies.

06:06.845 --> 06:08.265
It means we have worked

06:08.325 --> 06:11.785
and tested our nanoparticles on the lung cancer cells,

06:11.785 --> 06:13.265
which is a 5 49.

06:13.805 --> 06:17.935
Um, in vitro the major parameters,

06:17.935 --> 06:19.575
what we have studied in our study,

06:20.085 --> 06:21.695
they include proliferation.

06:22.535 --> 06:23.535
Proliferation is one

06:23.535 --> 06:26.535
of the major mechanism in the cancer study,

06:26.825 --> 06:28.415
which involves the rapid growth

06:28.555 --> 06:29.975
or reproduction of the cells.

06:30.155 --> 06:32.655
It means quite a number of the cells they quickly grow.

06:33.905 --> 06:35.525
So we have studied proliferation

06:35.745 --> 06:37.845
and growing of the cancerous cell is not good.

06:38.465 --> 06:40.965
The second thing, what we have studied is migration.

06:41.225 --> 06:44.525
So your cells can easily move from one part to another part

06:44.905 --> 06:46.845
and the tumor mass can detach

06:46.985 --> 06:48.885
and it can form a multicellular group.

06:48.905 --> 06:52.445
It can penetrate into the surrounding tissues, you know, so,

06:52.505 --> 06:54.965
so the second thing, what we have studied is migration.

06:55.505 --> 06:58.605
We have also studied various other exa

06:59.105 --> 07:02.565
ex experiments like cell migration, cell, cell count,

07:02.825 --> 07:07.325
and and finally we have identified various proteins

07:07.705 --> 07:10.405
and genes which are actually causing

07:11.145 --> 07:13.045
the pathogenesis of lung cancer.

07:13.545 --> 07:15.125
But when we have actually treated

07:15.155 --> 07:16.965
with our berberine nanoparticles,

07:17.195 --> 07:19.685
they reduces all those proteins

07:19.785 --> 07:22.205
and genes which are responsible for the cancer.

07:23.225 --> 07:24.965
Now let me tell you how exactly

07:25.025 --> 07:27.365
and what proteins we have been involved with.

07:27.865 --> 07:31.045
Now, first of all, we have prepared those nanoparticles

07:31.265 --> 07:34.285
and those nanoparticles were being optimally characterized

07:34.285 --> 07:37.045
because we cannot just give the nanoparticles as we design.

07:37.065 --> 07:40.085
We have to make sure that they are having a proper

07:40.635 --> 07:42.845
optimized favorable particle size.

07:43.785 --> 07:46.885
So enough drug has been encapsulated in the nanoparticles

07:47.185 --> 07:50.045
and it also has a good drug release

07:50.265 --> 07:51.645
for a longer duration of time.

07:52.895 --> 07:55.435
So we have first of all, prepared the nanoparticles

07:55.435 --> 07:56.595
and characterized for their

07:56.835 --> 07:58.115
physical chemical characterization.

07:58.845 --> 08:02.395
After that, we treated those nanoparticles.

08:02.395 --> 08:04.915
Once they are optimized with the A 5 49 cells,

08:04.915 --> 08:08.885
which are the lung cancer cells, when we have treated those,

08:09.265 --> 08:13.085
we measured the mRNA level, which is the qPCR r

08:13.085 --> 08:15.765
what we run the mRNA level of various tumor

08:16.415 --> 08:17.605
associated genes.

08:17.825 --> 08:20.965
And the various tumor associated genes we have looked at in

08:21.065 --> 08:25.365
in it involves P 10, P 53, and KRT 18.

08:25.865 --> 08:27.645
Now these are the protein expressions.

08:27.995 --> 08:30.645
They, we have measured even with the,

08:30.645 --> 08:32.205
human oncology protein array

08:33.385 --> 08:37.365
and we have clearly seen that when the cells are treated

08:37.475 --> 08:40.205
with the nanoparticles containing berberine,

08:40.225 --> 08:43.925
the liquid crystalline nanoparticles, they actually reduces

08:44.065 --> 08:47.565
or they decrease the proliferation, which I said

08:47.565 --> 08:50.365
that the cell growth, the migration

08:50.545 --> 08:52.445
of those cancerous cells,

08:52.785 --> 08:55.805
and even the colon colony forming of those cancerous cells

08:55.945 --> 09:00.045
of a 5 49 in a dose dependent manner where

09:00.115 --> 09:03.685
what we have observed it actually upregulate the two

09:03.685 --> 09:05.485
particular mRNA level.

09:05.625 --> 09:07.965
One is the P 10 and P 53,

09:08.655 --> 09:12.515
and it also downregulate in terms of the genes KRT 18,

09:12.685 --> 09:16.235
which is so, so the downregulation of KRT 18

09:16.335 --> 09:19.835
and the upregulation of P 10 and P 53 is good

09:19.985 --> 09:22.355
because that can help actually reduces the

09:22.515 --> 09:23.555
pathogenesis of the drug.

09:24.615 --> 09:27.635
And when we looked actually at the protein expression,

09:28.015 --> 09:31.115
we have looked at various number of proteins in,

09:31.455 --> 09:34.195
and those proteins were directly related

09:35.205 --> 09:38.215
with the various mechanism and the processes.

09:38.235 --> 09:39.335
We have looked in cancer

09:39.955 --> 09:44.695
and that involves proliferation, that involve metastasis

09:44.755 --> 09:46.415
or what we call as a migration.

09:47.325 --> 09:50.025
Now, in terms of the proteins, what we have looked

09:50.025 --> 09:54.505
through the human oncology protein ra, that includes A XL

09:55.685 --> 10:00.305
CA nine, her one, two, up to three, her one,

10:00.405 --> 10:04.505
her two, and HER three P-R-G-N-P dgf, aa,

10:05.245 --> 10:09.905
dkk one cts, P-B-C-L-X, CSF one

10:09.965 --> 10:11.065
and CAPG.

10:11.445 --> 10:12.905
Now they, these all proteins,

10:12.905 --> 10:15.905
what happen when someone have cancer, they usually go up.

10:16.095 --> 10:18.505
They are very, up-regulated,

10:18.525 --> 10:20.985
but when we are treating with the berberine nanoparticles,

10:20.985 --> 10:24.065
they actually reduce what we have shown and which is good.

10:24.285 --> 10:26.665
So all these proteins, what have been saying,

10:26.735 --> 10:29.505
they are involved with the proliferation and metastasis.

10:29.975 --> 10:32.185
Once you treat with the Burberry nanoparticles,

10:32.185 --> 10:33.345
they get downregulated.

10:33.725 --> 10:35.665
And once they all are downregulated,

10:35.805 --> 10:38.625
it means it reduces the pathogenesis of the drug.

10:39.975 --> 10:42.435
And so we have clearly seen on a gene level,

10:43.015 --> 10:44.635
at the gene level, as I mentioned,

10:44.695 --> 10:48.035
we have seen the upregulation of P 10 and P 53.

10:48.695 --> 10:52.355
And also in terms of the proteins, the numerous proteins,

10:52.355 --> 10:55.715
which I have mentioned just now, they all are downregulated

10:55.715 --> 10:57.795
with the treatment of bine loaded,

10:57.795 --> 10:59.635
liquid nano crystalline nanoparticles.

11:00.565 --> 11:01.785
So overall in this study,

11:02.125 --> 11:04.425
we have prepared these novel nanoparticles.

11:04.765 --> 11:07.905
We have not prepared the journalized nanoparticles,

11:07.905 --> 11:10.625
which various researchers they normally do across

11:10.625 --> 11:13.345
the globe using the polymeric nanoparticles.

11:13.345 --> 11:15.385
We have done an another high level

11:15.485 --> 11:16.905
of the nanoparticles called

11:16.925 --> 11:18.905
as a liquid crystalline nanoparticles.

11:19.445 --> 11:22.305
Now this nanoparticles we have prepared,

11:22.805 --> 11:23.865
we have characterized,

11:24.085 --> 11:28.585
and we have also actually done all the in vitro studies in

11:28.585 --> 11:30.705
terms of the genes and proteins, which I mentioned.

11:31.095 --> 11:33.385
This study was a quite a collaborative study

11:33.765 --> 11:35.425
and it'd been done across different

11:35.665 --> 11:37.265
geographical location across the globe.

11:37.365 --> 11:40.865
The the researchers on this study was from uk,

11:41.135 --> 11:43.265
from Australia, from Saudi Arabia,

11:43.455 --> 11:45.265
from India, and from Malaysia.

11:46.515 --> 11:49.415
Uh, it was quite an inter interdisciplinary study

11:49.485 --> 11:52.575
because that involves not only just the one area

11:52.635 --> 11:55.405
of a drug delivery and making the new nanoparticles,

11:55.865 --> 11:57.645
it was the study which was actually

11:57.645 --> 11:59.565
involving the drug delivery.

12:00.025 --> 12:03.325
It was a study which was also involving the pharmacology

12:03.825 --> 12:06.245
and as well as the area of immunology.

12:06.585 --> 12:09.685
Now all these three interdisciplinary area are sitting in

12:09.685 --> 12:12.445
this, and the different researchers in this different

12:12.675 --> 12:14.445
expertise were involved in that,

12:14.445 --> 12:16.725
where I was the primary lead in this study.

12:17.895 --> 12:21.235
Now, so this is the whole layout of the study

12:21.375 --> 12:24.315
and also the methodology, what we have used in our study

12:25.175 --> 12:27.875
and how burberine actually have shown the,

12:27.875 --> 12:30.395
therapeutic effectiveness in treating the small

12:30.505 --> 12:31.835
non-small cell lung cancer.

12:32.175 --> 12:34.955
The major difference, what we have clearly seen in our study

12:35.055 --> 12:37.155
is the, there, there are a lot of previous study.

12:37.155 --> 12:41.195
There's, I think when people have not really dig into

12:41.195 --> 12:43.035
the lung cancer too much using burberine,

12:43.035 --> 12:44.715
there was only one study, but in

12:44.715 --> 12:48.715
that study they have used burberine up to 90 micromolar.

12:49.135 --> 12:51.795
And when they have used that, such a high concentration

12:51.795 --> 12:54.435
and they have also used it for 24 hours incubation period.

12:55.655 --> 12:58.595
But the findings of our study has established a greater pot

12:58.595 --> 13:01.075
potential of berberine, and we have clearly shown

13:01.075 --> 13:03.595
that the loading of the berberine in a fight,

13:03.865 --> 13:07.115
roil based liquid crystaline nanoparticle formulation, they

13:07.715 --> 13:11.835
actually significantly inhibit the cell proliferation,

13:12.335 --> 13:16.715
the migration and the colony formation in a 5 49 cells up

13:16.715 --> 13:19.195
to the five micromolar burberine concentration.

13:19.215 --> 13:21.115
So it means the patients don't have to go

13:21.415 --> 13:24.475
for a very high dose, they can even go with a smaller dose,

13:24.855 --> 13:27.355
and burberine is commonly available in the,

13:28.025 --> 13:31.285
around the globe on the most of these cist shelves

13:31.425 --> 13:32.645
as a nutraceuticals.

13:33.105 --> 13:35.085
But it's, it's much advisable.

13:35.085 --> 13:36.285
People do take it as a

13:36.285 --> 13:37.885
nutraceuticals in their daily routine.

13:37.995 --> 13:41.325
However, it is always advisable if any, any patient

13:41.545 --> 13:43.005
or any person have a lung cancer.

13:43.065 --> 13:47.045
It is good to have a, consultancy first

13:47.155 --> 13:50.845
with the clinician so that it should not lead to any kind

13:50.845 --> 13:53.725
of the adverse and side effects despite it a nutraceutical.

13:54.425 --> 13:57.485
And, and that's why, the ENT role based nano

13:58.045 --> 14:00.085
delivery system containing burberine in one

14:00.085 --> 14:03.285
of the promising candidate, to treat the lung cancer.

14:03.555 --> 14:05.645
This is what is what we have shown in our study.

14:05.905 --> 14:09.485
But in our study, what we have clearly shown it is showing a

14:09.485 --> 14:10.805
significant inhibition

14:10.985 --> 14:14.445
of a 5 49 cell proliferation migration

14:14.505 --> 14:18.165
and colon colon formation at even just the five micromolar

14:18.165 --> 14:19.805
of the burberine concentration.

14:20.505 --> 14:24.925
So in nutshell, I can say that the, our berberine,

14:24.925 --> 14:28.005
liquid crystalline nanoparticles formulations,

14:28.235 --> 14:31.565
they can potentially actually address the low solubility,

14:32.265 --> 14:35.845
the low oral bio viability, the low efficacy,

14:35.865 --> 14:37.805
and the adverse side effects of burberine.

14:38.465 --> 14:41.925
The PHY is one of a very good polymer that has been used

14:41.945 --> 14:43.645
for the novel drug delivery system

14:43.905 --> 14:45.365
to incorporate the berberine,

14:45.465 --> 14:48.885
and it's a promising delivery candidate, to treat the,

14:49.065 --> 14:50.405
lung cancer in future.

14:51.065 --> 14:52.925
At this stage, we have,

14:53.225 --> 14:56.485
we are successful in developing these, beautiful

14:57.105 --> 14:59.885
eff efficacious, nanoparticles

15:00.265 --> 15:03.565
and we have only tested so far on the in vitro models.

15:04.225 --> 15:07.205
We have also extended our study in the cigarette smoke

15:07.205 --> 15:09.765
induced chronic obstructive pulmonary disease,

15:09.975 --> 15:11.765
which is also called emphysema.

15:12.065 --> 15:14.325
And one of our, that study also is published

15:14.345 --> 15:15.925
and we have also shown, shown

15:15.925 --> 15:18.485
that these nanoparticles are also effective in

15:18.645 --> 15:19.885
treating COPD as well.

15:20.385 --> 15:24.005
Uh, alongside it means reducing the symptoms of the COPD

15:24.185 --> 15:25.245
as well as in lung cancer.

15:26.145 --> 15:28.285
But both of these studies are only been done

15:28.345 --> 15:29.445
at an in vitro level.

15:30.065 --> 15:31.445
At this stage in our lab,

15:31.505 --> 15:33.405
we are currently been moving forward

15:33.505 --> 15:36.365
to do these studies in the animal models of the lung cancer

15:36.545 --> 15:40.565
and COPD and then moving from that, it would be really nice

15:40.565 --> 15:43.285
to see if they show really a quite an efficacious

15:43.285 --> 15:45.485
therapeutic effectiveness in in vivo models,

15:45.875 --> 15:48.085
then it can be taken to the human trials.

15:48.785 --> 15:52.005
So, and finally, alongside at this point of time, we are,

15:52.005 --> 15:53.925
what we are also doing is we are also trying

15:53.925 --> 15:55.725
to encapsulate these, sorry.

15:55.825 --> 15:58.725
We are also trying to actually embed these nanoparticles

15:59.035 --> 16:01.405
into the leak, into the dry powder inhalers.

16:01.745 --> 16:04.285
And we are very closely working with one of the company,

16:04.285 --> 16:07.925
which is the respiratory, specific company,

16:07.985 --> 16:10.805
and they're helping us actually translating our developed

16:10.805 --> 16:13.605
nanoparticles testing into the simulated human models

16:13.745 --> 16:16.045
to see the deposition in the lungs

16:16.215 --> 16:19.005
where exactly those nanoparticles are sitting, so

16:19.005 --> 16:21.805
that an optimal design of the delivery system can be made

16:22.025 --> 16:25.605
and can be used further drown down the translational path.

"Innovative Approaches in Lung Cancer Treatment: Exploring the Efficacy of Berberine-Loaded Liquid Crystalline Nanoparticles"**

00:00:00 - I in terms of my laboratory, I'm based at the Graduate School of Health and Discipline of Pharmacy at University of Technology Sydney, where my research team primarily focus on various lung diseases with the main emphasis on lung cancer, asthma, and COPD. Now, in today's study, we are going to talk more about and discuss about the phytol, loaded, liquid crystalline nanoparticles containing berberine. So we have understand, and we have studied the efficacy of these nanoparticles in lung cancer. Lung cancer is actually highly prevalent cancer, and with over more than 2 million new cases in the worldwide, it reported in just 2020
00:00:43 - Now, this lung cancer is one of the major cause of the deaths globally, and if we look at the statistics, there are around 1.79 million reported deaths, which contributes to almost 18% of the total cancer deaths around the globe in 2020. Now, there are two types of the lung cancer. One is called as a small cell lung cancer, other is called as a non-small cell lung cancer. Our studies emphasized and focused on the non-small cell lung cancer. This why we have studied on non-small cell lung cancer because this is a cancer which actually makes up to 85% of the lung cancer cases, and it is, it still remains a major most common
00:01:25 - Among the both, the only difference between both of these is that the small cell lung cancer is still an aggressive one, but the nonsmall cell lung cancer, because of its high prevalence, we have undertook this study. The, the small cell lung cancer. In, in, in that cancer, it's a metastasis is more as compared to the non-small cell cancer, which mostly happened in the lymph nodes. In our study we have, we undertook a study on a natural compound because around the globe people are getting very much aware nowadays about the alternative and complementary medicine. Everyone think and takes one or the other form of the natural compound in their diet or
00:02:09 - The best example, which I usually give in every talk is when someone really want to even lose a weight, they go on their diet with salad. And that salad actually is itself is nothing, but it's a kind of, plant-based products, which you are eating and to cut your certain metabolism into the body. In a same way, the pharmaceuticals are having an abundant therapeutic potential. In this study, we have used berberine. Berberine actually, in scientific terms is an isoc and alkaloid. It is actually also been available in the market in terms of the chemical compounds called as berberine hydrochloride.
00:02:54 - and for long ago by Chinese and also in the Ayurvedic medicine to treat various elements like diabetes, high cholesterol, high blood pressure, and various other conditions. But it was not explored on lung cancer. And this is how our study came into the picture, and we were the first one who demonstrated that it is quite effective in the small non-small cell lung cancer. Now, this article has been really got a very high alt metric. It has already been posted by, across the globe by multiple news channels. And so what we have seen here is that all these berberine,
00:03:34 - they can treat several metabolic health condition, as I mentioned. But there is a problem with this perine. The burberine itself is a very water insoluble and because of its poorly water-soluble nature, its absorption in the body is very low, and that can even cause toxicity if being given at a higher doses. So because its absorption is low, and in scientific term, we usually call it as an bioavailability. So the bioavailability of this drug is very, very low because it's poorly water-soluble. So what we have used in our studies, we have used a very advanced novel concept of nanoparticles.

Innovative Nanoparticle Design for Enhanced Drug Delivery in Lung Cancer Treatment

00:04:16 - The best example I can give is like a tennis ball, and it is hollow from inside and you fill your drug in the middle, in the hollow part of the tennis ball, the outer part of the tennis ball is a polymer sheath. In our case, we have used python roll is a polymer. So when it's been gone in and and and been taken up by the organ or the tissue, which is lung hair, it retains on the surface and it slowly dissolved the polymer and the drug release for a longer duration of time. So it means the patient don't have to take multiple dose, the patient have a better compliance, and it also reduces the side effect.
00:04:58 - and useful nature of these nanoparticle is it helps even also improving the solubility of berberine. So when berberine is already poorly water soluble and we prepare in form of a nanoparticles, it releases the drug for a longer duration of time. That's the whole idea and the concept we have used in our study. That's a very good question actually. It's, this is a question which is, this is what we have actually probed and elucidated in our study how exactly it had worked out. So what we have done, as I mentioned, that it has been incorporated into a liquid crystalline
00:05:38 - we are still been trying to get it into a dry powder inhaler so that when patient can have a puff, it can go directly on and deposit on the epithelial cells and release the drug. Now, before, actually I can tell you more in terms of the, how the mechanism has happened. It is really important to know what is the methodology we have used in the study. Now, in this study we have, we have done all the in vitro studies. It means we have worked and tested our nanoparticles on the lung cancer cells, which is a 5 49. in vitro the major parameters,
00:06:20 - they include proliferation. Proliferation is one of the major mechanism in the cancer study, which involves the rapid growth or reproduction of the cells. It means quite a number of the cells they quickly grow. So we have studied proliferation and growing of the cancerous cell is not good. The second thing, what we have studied is migration. So your cells can easily move from one part to another part and the tumor mass can detach and it can form a multicellular group. It can penetrate into the surrounding tissues, you know, so, so the second thing, what we have studied is migration. We have also studied various other exa
00:07:02 - and and finally we have identified various proteins and genes which are actually causing the pathogenesis of lung cancer. But when we have actually treated with our berberine nanoparticles, they reduces all those proteins and genes which are responsible for the cancer. Now let me tell you how exactly and what proteins we have been involved with. Now, first of all, we have prepared those nanoparticles and those nanoparticles were being optimally characterized because we cannot just give the nanoparticles as we design. We have to make sure that they are having a proper
00:07:43 - So enough drug has been encapsulated in the nanoparticles and it also has a good drug release for a longer duration of time. So we have first of all, prepared the nanoparticles and characterized for their physical chemical characterization. After that, we treated those nanoparticles. Once they are optimized with the A 5 49 cells, which are the lung cancer cells, when we have treated those, we measured the mRNA level, which is the qPCR r what we run the mRNA level of various tumor associated genes. And the various tumor associated genes we have looked at in

"Investigating the Impact of Berberine-Loaded Liquid Crystalline Nanoparticles on Cancer Cell Proliferation and Protein Expression"

00:08:25 - Now these are the protein expressions. They, we have measured even with the, human oncology protein array and we have clearly seen that when the cells are treated with the nanoparticles containing berberine, the liquid crystalline nanoparticles, they actually reduces or they decrease the proliferation, which I said that the cell growth, the migration of those cancerous cells, and even the colon colony forming of those cancerous cells of a 5 49 in a dose dependent manner where what we have observed it actually upregulate the two
00:09:05 - One is the P 10 and P 53, and it also downregulate in terms of the genes KRT 18, which is so, so the downregulation of KRT 18 and the upregulation of P 10 and P 53 is good because that can help actually reduces the pathogenesis of the drug. And when we looked actually at the protein expression, we have looked at various number of proteins in, and those proteins were directly related with the various mechanism and the processes. We have looked in cancer and that involves proliferation, that involve metastasis
00:09:47 - Now, in terms of the proteins, what we have looked through the human oncology protein ra, that includes A XL CA nine, her one, two, up to three, her one, her two, and HER three P-R-G-N-P dgf, aa, dkk one cts, P-B-C-L-X, CSF one and CAPG. Now they, these all proteins, what happen when someone have cancer, they usually go up. They are very, up-regulated, but when we are treating with the berberine nanoparticles, they actually reduce what we have shown and which is good. So all these proteins, what have been saying,
00:10:29 - Once you treat with the Burberry nanoparticles, they get downregulated. And once they all are downregulated, it means it reduces the pathogenesis of the drug. And so we have clearly seen on a gene level, at the gene level, as I mentioned, we have seen the upregulation of P 10 and P 53. And also in terms of the proteins, the numerous proteins, which I have mentioned just now, they all are downregulated with the treatment of bine loaded, liquid nano crystalline nanoparticles. So overall in this study, we have prepared these novel nanoparticles. We have not prepared the journalized nanoparticles,
00:11:10 - the globe using the polymeric nanoparticles. We have done an another high level of the nanoparticles called as a liquid crystalline nanoparticles. Now this nanoparticles we have prepared, we have characterized, and we have also actually done all the in vitro studies in terms of the genes and proteins, which I mentioned. This study was a quite a collaborative study and it'd been done across different geographical location across the globe. The the researchers on this study was from uk, from Australia, from Saudi Arabia, from India, and from Malaysia. it was quite an inter interdisciplinary study
00:11:52 - of a drug delivery and making the new nanoparticles, it was the study which was actually involving the drug delivery. It was a study which was also involving the pharmacology and as well as the area of immunology. Now all these three interdisciplinary area are sitting in this, and the different researchers in this different expertise were involved in that, where I was the primary lead in this study. Now, so this is the whole layout of the study and also the methodology, what we have used in our study and how burberine actually have shown the, therapeutic effectiveness in treating the small

Exploring the Efficacy of Berberine-Loaded Liquid Crystalline Nanoparticles in Lung Cancer Treatment**

00:12:32 - The major difference, what we have clearly seen in our study is the, there, there are a lot of previous study. There's, I think when people have not really dig into the lung cancer too much using burberine, there was only one study, but in that study they have used burberine up to 90 micromolar. And when they have used that, such a high concentration and they have also used it for 24 hours incubation period. But the findings of our study has established a greater pot potential of berberine, and we have clearly shown that the loading of the berberine in a fight, roil based liquid crystaline nanoparticle formulation, they actually significantly inhibit the cell proliferation,
00:13:16 - to the five micromolar burberine concentration. So it means the patients don't have to go for a very high dose, they can even go with a smaller dose, and burberine is commonly available in the, around the globe on the most of these cist shelves as a nutraceuticals. But it's, it's much advisable. People do take it as a nutraceuticals in their daily routine. However, it is always advisable if any, any patient or any person have a lung cancer. It is good to have a, consultancy first with the clinician so that it should not lead to any kind of the adverse and side effects despite it a nutraceutical.
00:13:58 - delivery system containing burberine in one of the promising candidate, to treat the lung cancer. This is what is what we have shown in our study. But in our study, what we have clearly shown it is showing a significant inhibition of a 5 49 cell proliferation migration and colon colon formation at even just the five micromolar of the burberine concentration. So in nutshell, I can say that the, our berberine, liquid crystalline nanoparticles formulations, they can potentially actually address the low solubility, the low oral bio viability, the low efficacy,
00:14:38 - The PHY is one of a very good polymer that has been used for the novel drug delivery system to incorporate the berberine, and it's a promising delivery candidate, to treat the, lung cancer in future. At this stage, we have, we are successful in developing these, beautiful eff efficacious, nanoparticles and we have only tested so far on the in vitro models. We have also extended our study in the cigarette smoke induced chronic obstructive pulmonary disease, which is also called emphysema. And one of our, that study also is published and we have also shown, shown
00:15:18 - treating COPD as well. alongside it means reducing the symptoms of the COPD as well as in lung cancer. But both of these studies are only been done at an in vitro level. At this stage in our lab, we are currently been moving forward to do these studies in the animal models of the lung cancer and COPD and then moving from that, it would be really nice to see if they show really a quite an efficacious therapeutic effectiveness in in vivo models, then it can be taken to the human trials. So, and finally, alongside at this point of time, we are, what we are also doing is we are also trying to encapsulate these, sorry. We are also trying to actually embed these nanoparticles
00:16:22 - And we are very closely working with one of the company, which is the respiratory, specific company, and they're helping us actually translating our developed nanoparticles testing into the simulated human models to see the deposition in the lungs where exactly those nanoparticles are sitting, so that an optimal design of the delivery system can be made and can be used further drown down the translational path.

Faculti AI can make mistakes

Research

Policy

Analysis